A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 1 Active not recruiting 12 enrolled Acerta Pharma BV

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study evaluates the safety, pharmacokinetics, pharmacodynamics and efficacy of acalabrutinib and ceralasertib (known as AZD6738) when taken in combination.

Timeline

Start: 2018-01-31
Primary completion: 2021-09-07
Completion: 2026-08-26

Publications

Jurczak W, Elmusharaf N, Fox CP, Townsend W, Paulovich AG, Whiteaker JR, Krantz F, Wun CC, Parr G, Sharma S, Munugalavadla V, Manwani R, Dean E, Munir T. Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia. Ther Adv Hematol. 2023 May 30;14:20406207231173489. doi: 10.1177/20406207231173489. eCollection 2023.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Acalabrutinib	Small molecule	100 mg	—
Subject	Ceralasertib	Small molecule	160 mg	—

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Summary

Timeline

Publications

Drugs

Indications